title: [Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances].
abstract: OBJECTIVE
  TNM staging system is used widely to predict prognosis of non-small cell lung carcinoma (NSCLC) patients, but patients with the same stage may have very different survivals; better prognostic index is needed. Angiogenesis is considered to be essential for tumor development, progression, and metastasis, but the prognostic impacts of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in NSCLC is controversial. This study was to evaluate the prognostic value of VEGF and MVD in NSCLC.
  
  
  METHODS
  VEGF and MVD in 214 specimens of stageI-II NSCLC (20 in stage IA, 137 in stage IB, and 57 in stage IIB) were detected by tissue chip and SP immunohistochemistry. No patient underwent postoperative antitumor treatment.
  
  
  RESULTS
  VEGF expression didn't relate to gender, age, blood type, pathologic type, and TNM stage (P0.05). MVD correlated with age and pathologic type (P0.05), but did not relate to gender, blood type, and TNM stage (P0.05). The mean value of MVD was 65.8+/-5.2 in VEGF-low patients, and 67.5+/-2.5 in VEGF-high patients (P0.05). The 5-year survival rate was significantly lower in MVD-high patients than in MVD-low patients (34.5% vs. 60.0%, P=0.013). Furthermore, multivariate Cox regression analysis showed that MVD (P=0.000) was an independent prognostic factor of NSCLC.
  
  
  CONCLUSIONS
  High MVD closely relates to poor prognosis of stageI-II NSCLC.
authors: Department of Thoracic Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
authors: Zhi-Hua
authors: ZH
authors: Zhu
authors: Tie-Hua
authors: TH
authors: Rong
authors: Can-Guang
authors: CG
authors: Zeng
authors: Qiu-Liang
authors: QL
authors: Wu
authors: Yun
authors: Y
authors: Ma
authors: Xiao-Ping
authors: XP
authors: Huang
authors: Bao-Jiang
authors: BJ
authors: Li
authors: Peng-Yuan
authors: PY
authors: Zhang
authors: Jin-Ming
authors: JM
authors: Zhao
authors: Wei
authors: W
authors: Hu
authors: Shi-Yi
authors: SY
authors: Zhang
authors: Hui
authors: H
authors: Yu
authors: Guo-Wei
authors: GW
authors: Ma
authors: Lan-Jun
authors: LJ
authors: Zhang
authors: Zhe-Sheng
authors: ZS
authors: Wen
authors: Jian-Hua
authors: JH
authors: Fu
authors: Hao
authors: H
authors: Long
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008833:Microcirculation / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D018952:Antigens, CD34; D042461:Vascular Endothelial Growth Factor A